Literature DB >> 28674118

Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Junne Kamihara1, Franck Bourdeaut2, William D Foulkes3, Jan J Molenaar4, Yaël P Mossé5, Akira Nakagawara6, Andreu Parareda7, Sarah R Scollon8, Kami Wolfe Schneider9, Alison H Skalet10, Lisa J States5, Michael F Walsh11, Lisa R Diller1, Garrett M Brodeur12.   

Abstract

Retinoblastoma (RB) is the most common intraocular malignancy in childhood. Approximately 40% of retinoblastomas are hereditary and due to germline mutations in the RB1 gene. Children with hereditary RB are also at risk for developing a midline intracranial tumor, most commonly pineoblastoma. We recommend intensive ocular screening for patients with germline RB1 mutations for retinoblastoma as well as neuroimaging for pineoblastoma surveillance. There is an approximately 20% risk of developing second primary cancers among individuals with hereditary RB, higher among those who received radiotherapy for their primary RB tumors. However, there is not yet a clear consensus on what, if any, screening protocol would be most appropriate and effective. Neuroblastoma (NB), an embryonal tumor of the sympathetic nervous system, accounts for 15% of pediatric cancer deaths. Prior studies suggest that about 2% of patients with NB have an underlying genetic predisposition that may have contributed to the development of NB. Germline mutations in ALK and PHOX2B account for most familial NB cases. However, other cancer predisposition syndromes, such as Li-Fraumeni syndrome, RASopathies, and others, may be associated with an increased risk for NB. No established protocols for NB surveillance currently exist. Here, we describe consensus recommendations on hereditary RB and NB from the AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res; 23(13); e98-e106. ©2017 AACRSee all articles in the online-only CCR Pediatric Oncology Series. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28674118      PMCID: PMC7266051          DOI: 10.1158/1078-0432.CCR-17-0652

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  110 in total

1.  Dysmorphic phenotype and neurological impairment in 22 retinoblastoma patients with constitutional cytogenetic 13q deletion.

Authors:  O Baud; V Cormier-Daire; S Lyonnet; L Desjardins; C Turleau; F Doz
Journal:  Clin Genet       Date:  1999-06       Impact factor: 4.438

2.  Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era.

Authors:  David H Abramson; Ira J Dunkel; Brian P Marr; Jasmine Francis; Y Pierre Gobin
Journal:  Am J Ophthalmol       Date:  2013-12       Impact factor: 5.258

3.  Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy.

Authors:  Roshan V Sethi; Helen A Shih; Beow Y Yeap; Kent W Mouw; Robert Petersen; David Y Kim; John E Munzenrider; Eric Grabowski; Carlos Rodriguez-Galindo; Torunn I Yock; Nancy J Tarbell; Karen J Marcus; Shizuo Mukai; Shannon M MacDonald
Journal:  Cancer       Date:  2013-10-02       Impact factor: 6.860

4.  Canadian guidelines for retinoblastoma care.

Authors:  Brenda Gallie
Journal:  Can J Ophthalmol       Date:  2009-12       Impact factor: 1.882

5.  Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma.

Authors:  Marcella Devoto; Claudia Specchia; Marci Laudenslager; Luca Longo; Hakon Hakonarson; John Maris; Yael Mossé
Journal:  Hum Hered       Date:  2011-07-06       Impact factor: 0.444

6.  PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations.

Authors:  Carmel McConville; Sarah Reid; Linda Baskcomb; Jenny Douglas; Nazneen Rahman
Journal:  Am J Med Genet A       Date:  2006-06-15       Impact factor: 2.802

Review 7.  Congenital central hypoventilation syndrome and Hirschsprung's disease.

Authors:  G D Croaker; E Shi; E Simpson; T Cartmill; D T Cass
Journal:  Arch Dis Child       Date:  1998-04       Impact factor: 3.791

8.  Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group.

Authors:  T Sawada; M Hirayama; T Nakata; T Takeda; N Takasugi; T Mori; K Maeda; R Koide; Y Hanawa; A Tsunoda
Journal:  Lancet       Date:  1984-08-04       Impact factor: 79.321

9.  Identification of ALK as a major familial neuroblastoma predisposition gene.

Authors:  Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

10.  Occurrence of Neuroblastoma among TP53 p.R337H Carriers.

Authors:  Ana Luiza Seidinger; Fernanda Paschoal Fortes; Maria José Mastellaro; Izilda Aparecida Cardinalli; Lilian Girotto Zambaldi; Simone Santos Aguiar; José Andrés Yunes
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

View more
  50 in total

Review 1.  Retinoblastoma, the visible CNS tumor: A review.

Authors:  Helen Dimaras; Timothy W Corson
Journal:  J Neurosci Res       Date:  2018-01-03       Impact factor: 4.164

2.  HOXB5 promotes retinoblastoma cell migration and invasion via ERK1/2 pathway-mediated MMPs production.

Authors:  Haiming Xu; Hailan Zhao; Jie Yu
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

Review 3.  Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.

Authors:  Emily S Tonorezos; Danielle Novetsky Friedman; Dana Barnea; Machteld I Bosscha; Guillermo Chantada; Charlotte J Dommering; Pim de Graaf; Ira J Dunkel; Armida W M Fabius; Jasmine H Francis; Mary-Louise C Greer; Ruth A Kleinerman; Wijnanda A Kors; Suzanne Laughlin; Annette C Moll; Lindsay M Morton; Petra Temming; Margaret A Tucker; Flora E van Leeuwen; Michael F Walsh; Kevin C Oeffinger; David H Abramson
Journal:  Ophthalmology       Date:  2020-05-15       Impact factor: 12.079

4.  An overview of neuroblastoma cell lineage phenotypes and in vitro models.

Authors:  Sheron Campos Cogo; Thatyanne Gradowski Farias da Costa do Nascimento; Fernanda de Almeida Brehm Pinhatti; Nilton de França Junior; Bruna Santos Rodrigues; Luciane Regina Cavalli; Selene Elifio-Esposito
Journal:  Exp Biol Med (Maywood)       Date:  2020-08-12

5.  Whole-body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update.

Authors:  Danielle Novetsky Friedman; Meier Hsu; Chaya S Moskowitz; Jasmine H Francis; Eric Lis; Megan Harlan Fleischut; Kevin C Oeffinger; Michael Walsh; Emily S Tonorezos; Charles A Sklar; David H Abramson; Ira J Dunkel
Journal:  Pediatr Blood Cancer       Date:  2020-05-09       Impact factor: 3.167

Review 6.  The genomic landscape of pediatric cancers: Implications for diagnosis and treatment.

Authors:  E Alejandro Sweet-Cordero; Jaclyn A Biegel
Journal:  Science       Date:  2019-03-15       Impact factor: 47.728

Review 7.  Imaging of cancer predisposition syndromes.

Authors:  Mary-Louise C Greer
Journal:  Pediatr Radiol       Date:  2018-08-04

8.  Variability in retinoblastoma genome stability is driven by age and not heritability.

Authors:  Ashley Polski; Liya Xu; Rishvanth K Prabakar; Xiaowu Gai; Jonathan W Kim; Rachana Shah; Rima Jubran; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry
Journal:  Genes Chromosomes Cancer       Date:  2020-06-09       Impact factor: 5.006

Review 9.  Genetic susceptibility to neuroblastoma: current knowledge and future directions.

Authors:  Laura E Ritenour; Michael P Randall; Kristopher R Bosse; Sharon J Diskin
Journal:  Cell Tissue Res       Date:  2018-03-27       Impact factor: 5.249

Review 10.  Whole-body magnetic resonance imaging of pediatric cancer predisposition syndromes: special considerations, challenges and perspective.

Authors:  Sandra Saade-Lemus; Andrew J Degnan; Michael R Acord; Abhay S Srinivasan; Janet R Reid; Sabah E Servaes; Lisa J States; Sudha A Anupindi
Journal:  Pediatr Radiol       Date:  2019-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.